Peptide-2 from mouse myostatin precursor protein alleviates muscle wasting in cancer-associated cachexia

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Cancer cachexia causes significant muscle wasting and is a major factor in cancer-related mortality.
• Myostatin (MSTN), also known as growth differentiation factor 8 (GDF-8), is a key regulator of skeletal muscle mass, and its inhibition is a therapeutic target for muscle wasting diseases.

Purpose of the Study:

• To evaluate the efficacy of peptide-2, derived from the MSTN prodomain, as an inhibitor of MSTN signaling for treating cancer cachexia.
• To assess the impact of peptide-2 on muscle mass, strength, and survival in a mouse model of cancer cachexia.

Main Methods:

• In vitro assessment of peptide-2's inhibitory effects on MSTN, activin, and GDF-11 signaling pathways.
• In vivo administration of peptide-2 via intramuscular injection to tumor-implanted mice to model cancer cachexia.
• Evaluation of muscle weight, muscle cross-sectional area, grip strength, heart weight, fat mass, and survival rates in treated and control mice.

Main Results:

• Peptide-2 selectively inhibited MSTN signaling without affecting activin signaling, and showed slight inhibition of GDF-11 signaling.
• Intramuscular injection of peptide-2 alleviated muscle wasting in cancer cachexia model mice, increasing gastrocnemius muscle weight and cross-sectional area.
• Peptide-2 enhanced grip strength and significantly improved survival rates in mice with cancer cachexia, despite not improving heart or fat mass loss.

Conclusions:

• Peptide-2 demonstrates potential as a therapeutic agent for mitigating muscle wasting associated with cancer cachexia.
• Inhibition of MSTN signaling via peptide-2 offers a promising strategy to improve muscle function and extend survival in cancer patients experiencing cachexia.